HCWB Key Statistics, Chart & Performance
The current stock price of HCWB is 1.275 USD. In the past month the price decreased by -10.21%. In the past year, price decreased by -88.54%.
HCWB Technical Analysis
HCWB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HCWB. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative.
HCWB Financial Highlights
Over the last trailing twelve months HCWB reported a non-GAAP Earnings per Share(EPS) of -13.92. The EPS increased by 65.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.48% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HCWB Forecast & Estimates
7 analysts have analysed HCWB and the average price target is 35.7 USD. This implies a price increase of 2700% is expected in the next year compared to the current price of 1.275.
For the next year, analysts expect an EPS growth of 79.82% and a revenue growth -23.55% for HCWB
HCWB Ownership
About HCWB
Company Profile
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Company Info
HCW BIOLOGICS INC
2929 N Commerce Pkwy, Miramar, Fl 33025
Miramar FLORIDA US
Employees: 36
Phone: 19548422024
HCW BIOLOGICS INC / HCWB FAQ
Can you describe the business of HCW BIOLOGICS INC?
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 36 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The firm is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
What is the stock price of HCW BIOLOGICS INC today?
The current stock price of HCWB is 1.275 USD. The price increased by 2.82% in the last trading session.
Does HCWB stock pay dividends?
HCWB does not pay a dividend.
How is the ChartMill rating for HCW BIOLOGICS INC?
HCWB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the growth outlook for HCW BIOLOGICS INC?
The Revenue of HCW BIOLOGICS INC (HCWB) is expected to decline by -23.55% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of HCW BIOLOGICS INC (HCWB)?
You can find the ownership structure of HCW BIOLOGICS INC (HCWB) on the Ownership tab.
What is the outstanding short interest for HCW BIOLOGICS INC?
The outstanding short interest for HCW BIOLOGICS INC (HCWB) is 0.64% of its float.